GSK's bepirovirsen achieved a functional cure in roughly one in five chronic hepatitis B patients in pivotal trial data, a result that positions the antisense oligonucleotide as potentially the most clinically meaningful advance in HBV therapeutics since the introduction of nucleos(t)ide analogues. The B-clear trial recorded a 9–10% rate of sustained HBsAg and HBV DNA loss at 24 weeks post-treatment in the overall population, according to PMC-published analysis — with a subset reaching approximately 20%, or one in five, under specific conditions. Science Magazine has framed bepirovirsen as a candidate to be the first treatment to bring functional cure within reach for more than a marginal fraction of the roughly 300 million people living with chronic HBV globally.

What "Functional Cure" Actually Means

The clinical definition matters here and is worth stating precisely. A functional cure for hepatitis B is the sustained loss of detectable hepatitis B surface antigen (HBsAg) alongside unquantifiable HBV DNA at 24 weeks off treatment — a threshold codified in current clinical literature, including a World Hepatitis Alliance briefing. The virus is not eradicated from hepatocytes — cccDNA persists — but it remains inactive and suppressed in the liver over the long term. This is the accepted bar against which all emerging HBV therapies are being measured, and it is meaningfully different from the virological suppression that current standard-of-care NAs achieve. Suppression requires indefinite treatment; functional cure, in principle, does not.

The only approved therapy that can produce HBsAg seroclearance — IFN-α — does so in approximately 10% of patients, per published data, and is frequently discontinued due to a well-characterized adverse-event profile that most clinicians consider intolerable as a routine treatment. A therapy that doubles or exceeds that clearance rate with a more manageable safety profile would reframe the treatment paradigm entirely.

Bepirovirsen's Phase 3 Entry and the Competitive Landscape

Bepirovirsen has now entered Phase 3 development, according to reporting from Labiotech, with the B-clear data providing the clinical justification for that progression. The drug functions as an antisense oligonucleotide targeting HBV RNA, suppressing production of all viral proteins — including HBsAg — across multiple transcripts derived from cccDNA and integrated HBV sequences. The breadth of that viral RNA targeting is one reason it can reduce HBsAg to undetectable levels, which most NA-only regimens cannot do.

Bepirovirsen is not alone in this space for long. AusperBio's AHB-137 has received clearance from China's Center for Drug Evaluation (CDE) to advance into Phase 3 trials, according to the same Labiotech source, part of a broader domestic Chinese effort to develop a locally developed HBV functional-cure drug. China carries a disproportionate share of the global HBV burden, and domestic regulatory and commercial pressure to produce approved therapeutics is real and well-funded.

In the combination-therapy segment, Brii Biosciences, Vir Biotechnology, and VBI Vaccines have announced initiation of a Phase 2 trial combining BRII-835 (VIR-2218, an RNAi agent targeting HBV) with BRII-179 (VBI-2601, a protein subunit immunogen). The pairing is a deliberate attempt to address both viral burden and immune reconstitution simultaneously — VIR-2218 drives HBsAg suppression while VBI-2601 aims to restore T-cell and antibody responses that are exhausted in chronic infection. Positive Phase 1b/2a data for VBI-2601 were presented at the International Liver Congress 2021, providing the immunogenicity rationale for moving into combination evaluation.

The RNAi Tier: Early But Promising

Further back in the pipeline, a new RNA interference candidate, KC13-M2G2, has shown preclinical data worth tracking. Published in Nature Communications, the compound produced dose-dependent reductions of HBsAg, HBV DNA, HBeAg, HBV S mRNA, and HBV total RNA in HepG2.2.15 cells without observable cytotoxicity. In rAAV-HBV mouse models covering both genotype B and C viral constructs, KC13-M2G2 inhibited plasma HBsAg, HBeAg, and HBV DNA, with durable suppression of HBsAg and HBV DNA at a 1 mg/kg dose. Animal model data do not translate directly to human outcomes, and the distance from here to a Phase 1 readout is substantial — but the mechanistic specificity and the breadth of viral markers targeted in vitro suggest a design that has been deliberately optimised for the functional-cure endpoint.

Why Combination Is Probably the Answer

The World Hepatitis Alliance's functional-cure briefing articulates the field's working hypothesis clearly: functional cure of HBV will most likely require a combination of agents targeting the virus at multiple steps, drawing on compounds that hit the virus directly, modulate the immune response, or both. This mirrors the approach that eventually cracked HIV — not a single-mechanism drug, but a combination that applied simultaneous pressure across viral replication, integration, and immune reconstitution. It also mirrors the HCV story, where direct-acting antivirals in combination drove cure rates from single digits to above 95% within a decade.

Those analogies are instructive without being perfectly applicable. HBV's episomal cccDNA reservoir and its tendency to integrate into the host genome create a persistence problem that neither HIV nor HCV poses in quite the same way. Clearing integrated sequences is not in any current drug's label or plausible near-term mechanism.

Covering the commercial internet buildout in the mid-1990s, one pattern recurred: the foundational technology — TCP/IP, HTML, the browser — was rarely the thing that changed user behaviour at scale. It was the combination of that infrastructure with distribution, content, and incentives that crossed the adoption threshold. The HBV functional-cure story has a similar shape: no single agent is likely to be sufficient, but the simultaneous maturation of several distinct mechanism classes — ASOs, RNAi, therapeutic vaccines, toll-like receptor agonists, capsid assembly modulators — means the components for a viable combination regimen are converging rather than diverging.

Adjacent Validation: Hepatitis Delta

It is worth noting that in the hepatitis delta space — HDV being the superinfection that dramatically worsens outcomes in HBV-coinfected patients — the FDA has now approved the first-ever treatment for hepatitis delta, offering clinical benefit to an estimated 80,000 Americans. That regulatory precedent, achieved in a disease with no prior approved therapy, provides some evidence that novel HBV-adjacent mechanisms can clear the FDA's evidentiary bar when clinical data are sufficiently robust.

Where the Pipeline Stands

The honest summary of the HBV functional-cure pipeline as of mid-2026: bepirovirsen is the furthest advanced asset with human efficacy data, and its one-in-five functional cure rate in a defined patient population is a meaningful step beyond what IFN-α achieves. The combination regimens — BRII-835 plus BRII-179 being the most clinically advanced — are in Phase 2, and their read-out data will be essential to understanding whether immune reconstitution adds clinically meaningful incremental benefit over viral suppression alone. AHB-137's Phase 3 clearance in China adds a competitive dimension to the space. And preclinical candidates like KC13-M2G2 suggest the RNAi design space has not been exhausted.

A complete, broadly applicable functional cure for chronic HBV is not yet at hand. The clinical consensus literature describes a pipeline in productive motion, with a meaningful goal clearly defined and multiple mechanism classes converging on it. The rate-limiting variable now is not scientific imagination — it is Phase 3 execution, regulatory timelines, and ultimately access: ensuring that whatever reaches approval reaches the patients in Southeast Asia, sub-Saharan Africa, and elsewhere who carry the majority of the global burden.